Evidence map›Paper›PMID 42306253›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026

Acetylator status-guided rapid reintroduction of isoniazid in tuberculosis patients with drug-induced hepatotoxicity.

Cynthia van Arkel, Ralf Stemkens, Cécile Magis-Escurra, Wouter Hoefsloot, Neeltje Carpaij, Jakko van Ingen, Reinout van Crevel, Arjan van Laarhoven, Rob Aarnoutse

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cynthia van ArkelDepartment of Pulmonary Diseases, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Ralf StemkensDepartment of Pharmacy, Pharmacology and Toxicology, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Cécile Magis-EscurraDepartment of Pulmonary Diseases, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Wouter HoefslootDepartment of Pulmonary Diseases, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Neeltje CarpaijDepartment of Pulmonary Diseases, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Jakko van IngenDepartment of Medical Microbiology, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Reinout van CrevelDepartment of Internal Medicine, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Arjan van LaarhovenDepartment of Internal Medicine, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.
Rob AarnoutseDepartment of Pharmacy, Pharmacology and Toxicology, Radboudumc Community for Infectious Diseases & Research Institute for Medical Innovation, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: People who slowly metabolize isoniazid are at increased risk of drug-induced liver injury (DILI) and interruption of tuberculosis treatment. We hypothesized that immediate identification of slow acetylators among patients with DILI will facilitate rapid and safe reintroduction of isoniazid. Methods: Between 2021 and 2023, at our tuberculosis referral centre in The Netherlands, we evaluated an isoniazid acetylator status-guided rapid reintroduction of anti-tuberculous drugs in a cohort of patients with DILI. Patients' acetylator status was determined by phenotyping after a single dose of isoniazid, regardless of liver function abnormalities. Results: In total, 49 tuberculosis patients underwent Therapeutic Drug Monitoring (TDM) from 2021 to 2023, with 67% being slow acetylators as assessed by phenotyping. Out of 10 patients with DILI, 8 were slow acetylators, and the total exposure to isoniazid (AUC Conclusion: In tuberculosis patients with DILI, assessment of isoniazid acetylator status can guide rapid reintroduction of isoniazid. Combined with AUC

Indexed as

Acetylator statusDrug induced hepatotoxicityIsoniazidReintroductionTuberculosis

Identifiers

PMID42306253
PMCPMC13266185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.